Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 1/2002

01-01-2002 | Current Opinion

Pharmacy Benefit Management

Enhancing the Applicability of Pharmacoeconomics for Optimal Decision Making

Authors: C. Daniel Mullins, Junling Wang

Published in: PharmacoEconomics | Issue 1/2002

Login to get access

Abstract

Previous research indicates that in order to make pharmacoeconomic information applicable and useful for pharmaceutical benefit management (PBM) companies, several aspects need to be considered and improved. These include: timely availability of information, head-to-head comparators, peer-reviewed publications, independent sponsorship of pharmacoeconomic studies, use of relevant populations in research and published pharmacoeconomic models, and pharmacoeconomics training for pharmaceutical companies’ sales personnel. In addition to these measures, guidelines have been playing an important role in improving the applicability of pharmacoeconomic information. This paper examines the progress to date in enhancing the applicability of pharmacoeconomics for optimal PBM decision making.
The greatest improvements have been made in enhancing the quality of pharmacoeconomic research and the quality of peer-reviewed publications. Direct comparator studies are starting to emerge, but in limited numbers. The need for additional training of pharmaceutical representatives and PBM staff members remains a critical issue.
Literature
1.
Grabowski H, Mullins CD. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc Sci Med 1997 Aug; 45 (4): 535–44
2.
Gagnon JP. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry? Am Heart J 1999 May; 137 (5): S62–6
3.
Shulman SR. Pharmacy benefit management companies (PBMs): why should we be interested? Pharmacoeconomics 1998; 14 Suppl 1: 49–56PubMed
4.
Balto DA. A whole new world?. Pharmaceutical responses to the managed care revolution. Food Drug Law J 1997; 52 (1): 83–98PubMed
5.
Clouse JC. Pharmacoeconomics: a managed care perspective. Top Hosp Pharm Manage 1994 Jan; 13 (4): 54–9
6.
Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999 Oct; 17 (10): 3333–55
7.
McInnes E, Cullum N, Nelson EA, et al. The development of a national guideline on the management of leg ulcers. J Clin Nurs 2000 Mar; 9 (2): 208–17
8.
Drake LA, Yale KP, Lowery BJ, et al. American Academy of Dermatology guidelines of care: development and process. Arch Dermatol 1997 Nov; 133 (11): 1369–74
9.
Sanchez LA. Pharmacoeconomics and formulary decision making. Pharmacoeconomics 1996; 9 Suppl.: 16–25PubMed
10.
Hatoum HT, Freeman RA. The use of pharmacoeconomic data in formulary selection. Top Hosp Pharm Manage 1994 Jan; 13 (4): 47–53
11.
Nuijten MJ, Starzewski J. Applications of modeling studies. Pharmacoeconomics 1998 Mar; 13 (3): 289–91
12.
Thomas N. The role of pharmacoeconomics in disease management: a pharmaceutical benefit management company perspective. Pharmacoeconomics 1996; 9 Suppl. 1: 9–15PubMed
13.
Bakst A. Pharmacoeconomics and the formulary decision-making process. Hosp Formul 1995 Jan; 30 (1): 42–50
14.
Miller JL. Conference explores impediments to meaningful treatment comparisons: demand for cost-effectiveness data is impetus. Am J Health Syst Pharm 1995 Jun; 52 (11): 1140, 1145-8
15.
Power EJ. Current efforts in standards development. United States. Med Care 1996 Dec; 34 (12 Suppl.): DS200–3; discussion DS204-7
16.
Sloan FA, Grabowski HG. Conclusions and implications. Soc Sci Med 1997 Aug; 45 (4): 645–7
17.
Johnson JA, Friesen E. Reassessing the relevance of pharmacoeconomic analyses in formulary decisions. Pharmacoeconomics 1998 May; 13 (5): 479–85
18.
MacPherson P. The FDA just says yes. Hosp Health Netw 1996 May; 70 (10): 34–6, 38
19.
Bootman JL. Pharmacoeconomics and outcomes research. Am J Health Syst Pharm 1995 Jul; 52 (14 Suppl. 3): S16–9
20.
Rajagopalan R, Kallal JE, Fowler Jr JF, et al. Practical issues in conducting pharmacoeconomic. Clin Ther 1996 Nov–Dec; 18 (6): 1298–306PubMed
21.
Chen C, Vlasses PH. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Consortium perspective: what constitutes a useful economic study? Am Heart J 1999 May; 137 (5): S71–4
22.
Henry D, Hill S. Comparing treatments [editorial]. BMJ 1995 May; 310 (6990): 1279
23.
Gorkin L, Botteman M, Sahu S, et al. Economic Analysis of Lipid Lowering Capability of Antihypertensive Medications in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1997; 96 (8S): I–184
24.
Newby LK, Eisenstein E, Califf RM, et al. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med 2000 Mar; 342 (11): 749–55
25.
Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000 Apr; 283 (16): 2116–21
26.
Minshall ME, Kody MC, Mosbacher F. Pharmacoeconomics research credibility: a controversial and recurring theme in health outcomes research. Med Care 1999 Apr; 37 (4 Suppl. Lilly): AS12–9
27.
Mullins CD, Merchant S. Guidelines and information requirements. In: Vogenberg FR, editor. Introduction to applied pharmacoeconomics. New York (NY): McGraw-Hill (Medical Publishing Division), 2001: 229–61
28.
Friedberg M, Saffran B, Stinson TJ, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999 Oct; 282 (15): 1453–7
29.
Drummond MF. A reappraisal of economic evaluation of pharmaceuticals science or marketing? Pharmacoeconomics 1998 Jul; 14 (1): 1–9
30.
Blumenthal D, Causino N, Campbell E, et al. Relationships between academic institutions and industry in the life sciences: an industry survey. N Engl J Med 1996 Feb; 334 (6): 368–73
31.
Horton R. Sponsorship, authorship, and a tale of two media. Lancet 1997 May; 349 (9063): 1411–2
32.
Thompson DF. Understanding financial conflicts of interest. N Engl J Med 1993 Aug; 329 (8): 573–6
33.
Mason J. Generalizability of pharmacoeconomic studies. Pharmacoeconomics 1997 Jun; 11 (6): 503–14
34.
Sanchez LA, Lee JT. Applied pharmacoeconomics: modeling data from internal and external sources. Am J Health Syst Pharm 2000 Jan; 57 (2): 146–55
35.
Thwaites R, Townsend RJ. Pharmacoeconomics in the new millennium: a pharmaceutical industry perspective. Pharmacoeconomics 1998 Feb; 13 (2): 175–80
36.
37.
Basskin L. How to evaluate the validity and usefulness of pharmacoeconomic literature. Hosp Formul 1997 Apr; 32: 407–8, 411-12, 415-6
38.
Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996
39.
Sullivan S, Mather D, Augenstein D, et al. Regence BlueShield Pharmacy Services: Guidelines for the submission of clinical and economic data supporting formulary consideration. Seattle: Regence BlueShield, University of Washington (WA), Version 1.3: Dec 1997
40.
41.
Johnson JA, Bootman JL. Pharmacoeconomic analysis in formulary decisions: an international perspective. Am J Hosp Pharm 1994 Oct; 51 (20): 2593–8
42.
Perloff JM, Veld KT. Modern industrial organization. 2nd ed. New York (NY): HarperCollins College Publishers, 1994
43.
Neumann PJ, Zinner DE, Paltiel AD. The FDA and regulation of cost-effectiveness claims. Health Aff 1996 Fall; 15 (3): 54–71
44.
Division of Drug Marketing, Advertising and Communications (DDMAC). Principles for the review of pharmacoeconomic promotion [draft report]. Rockville (MD): Food and Drug Administration (FDA), 1995 Mar 20
45.
Anonymous. Will health care economic information lead to therapeutic-class warfare or welfare? Harv Law Rev 1998; 111 (8): 2384–401
46.
Morris LA. Product labeling and pharmacoeconomic information. Am Heart J 1999; 137: S78–80PubMed
47.
Reinhardt UE. Making economic evaluations respectable. Soc Sci Med 1997; 45 (4): 555–62PubMed
Metadata
Title
Pharmacy Benefit Management
Enhancing the Applicability of Pharmacoeconomics for Optimal Decision Making
Authors
C. Daniel Mullins
Junling Wang
Publication date
01-01-2002
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 1/2002
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200220010-00002

Other articles of this Issue 1/2002

PharmacoEconomics 1/2002 Go to the issue

Commentary

Economic Evaluation of Vaccination Programmes

Review Article

Onychomycosis

Original Research Article

Antihypertensive Treatment with and without Benazepril in Patients with Chronic Renal Insufficiency

Original Research Article

Economic Comparison of Leflunomide and Methotrexate in Patients with Rheumatoid Arthritis

Original Research Article

Economic Impact of Low Dose Polyethylene Glycol 3350 Plus Electrolytes Compared with Lactulose in the Management of Idiopathic Constipation in the UK